Skip to main content
. 2021 Aug 2;131(15):e131178. doi: 10.1172/JCI131178

Figure 2. Class IIa HDAC inhibition suppresses EndMT-associated changes in mRNA and protein levels.

Figure 2

(A–C) qRT-PCR analysis of endothelial (ZO2, ICAM2; n = 3), mesenchymal (SM22α, FAP; n = 4), and TGF-β pathway (SNAIL, SLUG; n = 4–6) transcript levels after 5-day EndMT induction with or without increasing doses of MC1568 in HCAECs. (D and E) Representative Western blots and densitometry measurements of endothelial (ZO2, ICAM2, CD31) and mesenchymal proteins (SM22α, αSMA, Vimentin) in HCAECs after 5-day EndMT with or without 7 μM MC1568 treatments compared with vehicle-treated controls. n = 5–6. (F) Representative Western blots and densitometry measurements of TGF-β–associated transcription factor proteins (SLUG, pSMAD2, pSMAD3) in HCAECs after 5-day EndMT with or without 7 μM MC1568 treatment compared with vehicle-treated controls. n = 4–6. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. Analyses performed using 1-way ANOVA (A–C) and 2-way ANOVA (D–F).